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background 
 
Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but
the risk associated with the various HPV types has not been adequately assessed.
 
methods
 
We pooled data from 11 case–control studies from nine countries involving 1918 wom-
en with histologically confirmed squamous-cell cervical cancer and 1928 control wom-
en. A common protocol and questionnaire were used. Information on risk factors was
obtained by personal interviews, and cervical cells were collected for detection of HPV
DNA and typing in a central laboratory by polymerase-chain-reaction–based assays
(with MY09/MY11 and GP5+/6+ primers).
 
results
 
HPV DNA was detected in 1739 of the 1918 patients with cervical cancer (90.7 percent)
and in 259 of the 1928 control women (13.4 percent). With the GP5+/6+ primer, HPV
DNA was detected in 96.6 percent of the patients and 15.6 percent of the controls. The
most common HPV types in patients, in descending order of frequency, were types 16,
18, 45, 31, 33, 52, 58, and 35. Among control women, types 16, 18, 45, 31, 6, 58, 35, and
33 were the most common. For studies using the GP5+/6+ primer, the pooled odds ra-
tio for cervical cancer associated with the presence of any HPV was 158.2 (95 percent
confidence interval, 113.4 to 220.6). The odds ratios were over 45 for the most com-
mon and least common HPV types. Fifteen HPV types were classified as high-risk types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 3 were classified as prob-
able high-risk types (26, 53, and 66); and 12 were classified as low-risk types (6, 11, 40,
42, 43, 44, 54, 61, 70, 72, 81, and CP6108). There was good agreement between our ep-
idemiologic classification and the classification based on phylogenetic grouping.
 
conclusions
 
In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73,
and 82 should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66
should be considered probably carcinogenic.
abstract
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ervical cancer is the second most
 
common cancer in women worldwide, and
it is the principal cancer of women in most
developing countries, where 80 percent of cases
occur.
 
1
 
 Molecular epidemiologic evidence clearly
indicates that certain types of human papilloma-
virus (HPV) are the principal cause of invasive cer-
vical cancer
 
2-4
 
 and cervical intraepithelial neopla-
sia.
 
5,6
 
 More than 80 HPV types have been identified,
and about 40 can infect the genital tract.
 
7
 
Genital HPV types have been subdivided into
low-risk types, which are found mainly in genital
warts, and high-risk types, which are frequently as-
sociated with invasive cervical cancer. There is, how-
ever, no consensus concerning the categorization
of many HPV types with low prevalence according
to risk. Moreover, the number of putative high-risk
types varies from 13 to 19, and only 11 HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, and 58) are
consistently classified as entailing high risk.
 
8-11
 
 For
these reasons, clear-cut criteria for classifying HPV
types into low-risk and high-risk groups are need-
ed. These criteria should be based on molecular ep-
idemiologic studies that provide risk estimates and
on functional evidence of the oncogenic potential
of the various HPV types. A classification of HPV
types based on their phylogenetic relationship has
been proposed,
 
12
 
 but it has not been tested epide-
miologically.
In 1995, the International Agency for Research
on Cancer (IARC) concluded that four case–control
studies yielded sufficient evidence to classify HPV
types 16 and 18 as human carcinogens, but the evi-
dence was limited or inadequate for other types.
 
13
 
Since then, we have completed seven additional
case–control studies in other populations, using
similar protocols and HPV DNA–detection assays.
We report here the pooled data from the 11 studies.
These results form the basis for an epidemiologic
classification of HPV types associated with cervical
cancer, which can be compared with the phyloge-
netic classification. This information is essential
for planning prevention by HPV vaccines and for
screening programs based on HPV testing.
 
study design
 
From 1985 to 1997, we conducted 11 studies in
nine countries with a broad range of rates of inci-
dence of cervical cancer. Nine studies dealt only with
invasive cervical cancer, and two also dealt with in
situ cervical cancer. The subjects were drawn from
high-risk populations in Africa (Morocco
 
14
 
 and
Mali
 
15
 
) and South America (Colombia,
 
2,16
 
 Brazil,
 
17
 
Paraguay,
 
18
 
 and Peru
 
19
 
); intermediate-risk popula-
tions in Asia (Thailand
 
20 
 
and the Philippines
 
21
 
);
and low-risk populations in Spain.
 
2,16 
 
The meth-
ods of selection of patients and controls are de-
scribed in the original study reports. Briefly, the
patients were women with newly diagnosed, histo-
logically confirmed invasive or in situ squamous-
cell cervical cancer who had not received treatment.
The control groups were population-based in the
studies of invasive cervical cancer in Spain and Co-
lombia and hospital-based or clinic-based in the
other studies. They were frequency-matched to pa-
tients according to age (in five-year intervals) in all
studies. The original histologic slides from which
the diagnosis was made were reviewed by expert
pathologists. All protocols were approved by the
IARC and local ethics committees. Oral consent
was obtained from the subjects in the Spanish and
Colombian studies (which were initiated in 1985),
consistent with the standard at the time. In the re-
maining studies, which were initiated later, written
informed consent was obtained.
 
collection of data and specimens
 
The women were interviewed at the hospital by
trained interviewers using a standardized ques-
tionnaire to elicit information on risk factors for
cervical cancer. After the interview, all women un-
derwent a pelvic examination performed by a gy-
necologist or nurse, and two cervical scrapings were
collected for cytologic study and detection of HPV
DNA. A tumor-biopsy specimen was taken from
most patients and kept frozen.
 
detection, typing, and phylogenetic 
grouping of hpv dna
 
Detection of HPV DNA in cervical scrapings (exfo-
liated cells) and biopsy specimens was performed
blindly in central laboratories with use of polymer-
ase-chain-reaction (PCR)–based assays. Detailed
protocols for these assays have been described. The
relatively insensitive version of PCR primers for the
 
L1
 
 gene, MY09/MY11, was used in the Colombian
and Spanish studies.
 
22
 
 The GP5+/6+ general pri-
mer system was used in the remaining studies.
 
23
 
To detect the specific HPV types, oligohybridiza-
tion methods were used for HPV types 16, 18, 31,
33, 35, 39, 45, 51, 52, 54, and 56. A second round
was performed for HPV types 6, 11, 26, 34, 40, 42,
c
methods
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43, 44, 53, 58, 59, and 68. A third round was per-
formed for HPV types 57, 61, 66, 70, 72, 73, 81
(CP8304), 82 (W13B/MM4 subtype and IS39 sub-
type), 83, and CP6108. Specimens that were posi-
tive on assays with the GP5+/6+ system but that did
not hybridize with any of these 33 probes were cod-
ed as HPV type X. Amplification of a fragment of
the 
 
b
 
-globin gene was used to assess the quality of
the target DNA.
For specimens from patients found to be neg-
ative for 
 
b
 
-globin and HPV DNA or positive for
HPV X, DNA was extracted from the cell pellets and
retested as described above. For detection of HPV
in biopsy specimens, the sandwich method was
used to check the histologic evidence of cancer,
and an additional HPV-type–specific PCR was per-
formed, with use of an E7 primer, for 14 HPV types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and
 
Table 1. Human Papillomavirus (HPV) Types in 1739 Patients with Squamous-Cell Cervical Cancer and in 259 Control Women Infected 
with Single or Multiple Types.
Infections with One HPV Type Infections with Multiple HPV Types
 
HPV Type Patients Controls HPV Types Patients Controls
 
no.
% of all
infected patients no. 
% of all
infected controls no. 
% of all
infected patients no. 
% of all
infected controls
 
16 950 54.6 63 24.3 16 and 18 36 2.1 3 1.2
18 192 11.0 19 7.3 16 and 33 9 0.5 0 0.0
45 77 4.4 9 3.5 16 and 31 6 0.3 1 0.4
31 59 3.4 11 4.2 16 and 45 3 0.2 0 0.0
52 38 2.2 4 1.5 16 and 51 3 0.2 0 0.0
33 35 2.0 4 1.5 16 and 56 2 0.1 0 0.0
58 34 2.0 6 2.3 16 and 58 2 0.1 0 0.0
35 24 1.4 7 2.7 16 and 66 2 0.1 0 0.0
59 20 1.2 1 0.4 16 and 6 2 0.1 0 0.0
51 13 0.7 4 1.5 16 and 73 2 0.1 0 0.0
56 11 0.6 5 1.9 16 and other types 5 0.3 2 0.8
39 9 0.5 0 0.0
73 6 0.3 1 0.4 18 and 45 9 0.5 1 0.4
82 5 0.3 0 0.0 18 and 33 4 0.2 0 0.0
26 3 0.2 0 0.0 18 and 52 3 0.2 1 0.4
66 3 0.2 0 0.0 18 and 26 2 0.1 0 0.0
68 2 0.1 1 0.4 18 and 58 2 0.1 0 0.0
HR* 2 0.1 0 0.0 18 and other types 2 0.1 1 0.4
53 1 0.1 0 0.0
6 1 0.1 6 2.3 31 and 33 3 0.2 0 0.0
81 1 0.1 6 2.3 31 and 52 2 0.1 0 0.0
11 1 0.1 2 0.8 31 and other types 2 0.1 4 1.5
43 0 0.0 3 1.2
40 0 0.0 2 0.8 33 and 35 3 0.2 1 0.4
42 0 0.0 1 0.4 33 and 58 3 0.2 0 0.0
44 0 0.0 1 0.4 33 and other types 2 0.1 1 0.4
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68) that were formerly designated as oncogenic
types.
 
4
 
 These procedures were also used for ream-
plification of all control specimens classified as
HPV X and a randomly selected subgroup of 32
specimens found to be positive for 
 
b
 
-globin and
negative for HPV DNA. After reamplification, 32
specimens from patients that were originally nega-
tive for HPV DNA were reclassified as positive for
HPV DNA, but none of the specimens from control
women were found to be positive for HPV DNA.
For patients, the combined prevalence of HPV
DNA in exfoliated cells and in biopsy specimens is
reported, whereas for control subjects, the preva-
lence of HPV DNA was determined only in exfoliat-
ed cells. Comparisons between patients and con-
trols in which only the results from exfoliated cells
were used produced virtually identical results.
For phylogenetic grouping of HPV types into
low-risk or high-risk groups, we used the phyloge-
netic tree of 106 papillomavirus types based on an
informative region within the 
 
L1
 
 gene.
 
24
 
 The 12
HPV types that had been classified phylogenetically
as high risk on the basis of sequence alignment,
 
12
 
together with the types that are related to those 12
types, were classified as phylogenetically high risk
in this study. Accordingly, among the 33 HPV types
that were specifically tested, types 16, 31, 33, 35, 52,
and 58 (all belonging to group A9); 18, 39, 45, 59,
68, and 70 (group A7); 26, 51, and 82 (group A5);
and 53, 56, and 66 (group A6) were phylogenetically
classified as high-risk HPV types. In contrast, types
6, 11, and 44 (group A10); 34 and 73 (group A11); 40
and 43 (group A8); 42 (group A1); 61, 72, 81, 83, 84,
and CP6108 (group A3); and 57 (group A4) were
classified as low-risk HPV types.
 
statistical analysis
 
To assess the risk of cervical cancer associated with
HPV types, odds ratios and 95 percent confidence
intervals were estimated by unconditional logistic
regression.
 
25
 
 Odds ratios were adjusted for age as a
categorical covariate (under 40, 40 to 49, 50 to 59,
and over 59 years). Because of the small number of
subjects from Mali, two categories were used (≤45
and >45 years). Odds ratios for individual HPV types
were estimated by categorizing, as a single variable,
each type or category of types. Subjects with HPV
DNA–negative results were used as the reference
category.
We defined as high-risk HPV types those associ-
 
* HR denotes that testing was performed for high-risk types, but that there was not sufficient material for further typing.
 
† HPV type X denotes specimens that were positive with the GP5+/6+ system but that did not hybridize with any of the 33 probes.
 
Table 1. (Continued.)
Infections with One HPV Type Infections with Multiple HPV Types
 
HPV Type Patients Controls HPV Types Patients Controls
 
no.
% of all
infected patients no.
% of all
infected controls no.
% of all
infected patients no.
% of all
infected controls
 
54 0 0.0 3 1.2
61 0 0.0 1 0.4 45 and 43 2 0.1 1 0.4
70 0 0.0 4 1.5 45 and other types 5 0.3 5 1.9
72 0 0.0 4 1.5
CP6108 0 0.0 1 0.4 6 and 11 1 0.1 4 1.5
X† 111 6.4 54 20.8
Other double
infections
10 0.6 4 1.5
Triple infections 11 0.6 5 1.9
Quadruple infections 3 0.2 1 0.4
Quintuple infections 0 0.0 1 0.4
Total no. of women
with single
infections
1598 91.9 223 86.1 Total no. of women 
with multiple
infections
141 8.1 36 13.9
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ated, as single infections, with an odds ratio for cer-
vical cancer of at least 5.0 and a lower 95 percent
confidence limit of at least 3.0, as well as those that
were detected in some of the patients but in none of
the controls. We defined as low-risk HPV types those
with an odds ratio for cervical cancer of at least 1.0
and a lower 95 percent confidence limit of less than
3.0, as well as those that were detected in some of
the controls but in none of the patients. To test for a
trend according to age in the prevalence of a specif-
ic HPV type among patients, the Mantel–Haenszel
linear trend test was used. The Mantel–Haenszel
test was used to test for homogeneity. All P values
are two-sided.
 
study subjects
 
A total of 2506 women with cervical cancer and
2491 control women were interviewed. Of the pa-
tients, 2365 (94.4 percent) had squamous-cell car-
cinoma and 141 (5.6 percent) had adenocarcinoma
or adenosquamous carcinoma. A total of 1990 of
the 2365 women with squamous-cell carcinoma
(84.1 percent) and 2126 of the 2491 control wom-
en (85.3 percent) provided cervical specimens for
HPV DNA testing.
Seventy-two of the 1990 specimens from patients
(3.6 percent) and 198 of the 2126 control specimens
(9.3 percent) tested for HPV DNA were negative for
both 
 
b
 
-globin and HPV and were excluded from the
analysis, leaving 1918 patients and 1928 controls
with specimens adequately tested for HPV DNA.
 
specific prevalence of hpv types
 
A total of 1739 patients (90.7 percent) were posi-
tive for HPV DNA. Of these, 91.9 percent were in-
fected with a single HPV type, and 8.1 percent were
infected with multiple types. Among control wom-
en, 259 (13.4 percent) were positive for HPV DNA;
of these, 86.1 percent were infected by a single HPV
type, and 13.9 percent were infected by multiple
types (Table 1). In the studies in which the GP5+/6+
primers were used, the prevalence of HPV DNA was
96.6 percent in patients and 15.6 percent in controls.
HPV types 16, 18, 45, 31, 33, 52, 58, and 35 (in de-
scending order of frequency) were the eight most
common types in patients, including infections with
both single and multiple HPV types. HPV types 16,
18, 45, 31, 6, 58, 35, and 33 were the eight most com-
mon types in controls. The proportion of uncharac-
terized HPV types (HPV type X) was higher in con-
trols (20.8 percent) than in patients (6.4 percent)
(Table 1). HPV types 34, 57, and 83 were not found
in any specimens from patients or controls.
HPV type 16 was the most common type in all
countries, with an overall prevalence of 58.9 per-
cent, ranging from 43.9 percent in the Philippines
to 72.4 percent in Morocco. HPV type 18 was the
second most common type, with an overall preva-
lence of 15.0 percent (lowest in Spain [3.7 percent]
and Colombia [4.4 percent] and highest in the Phil-
ippines [27.9 percent]). The third most common
type, HPV type 45 (5.9 percent), had a very low prev-
alence in Spain and Colombia (0.8 percent and 0.6
percent, respectively), and its highest prevalence
was in the Philippines (15.7 percent). HPV types 31
and 35 were more common in Latin America than
in the other study areas. The prevalence of HPV type
52 was highest in Peru (8.6 percent). Some of the
differences in type-specific prevalence observed be-
tween Spain and Colombia and the other countries
could be related, at least in part, to differences in
the sensitivities of the PCR assays used.
To explore the possibility of trends in the preva-
lence of HPV over time, the patients and controls
were stratified into three groups according to age
(Table 2). No statistically significant differences ac-
cording to age in the distribution of HPV types (as
single or multiple infections) were observed among
the control women. Among the patients, the preva-
lence of HPV type 16 decreased significantly with
age. Increases in prevalence with age were observed
for types 39, 52, and 58.
 
risk associated with hpv
 
The prevalence of HPV DNA among patients and
controls and the corresponding odds ratios, adjust-
ed for age, are presented in Table 3 according to
country. In the studies in which the GP5+/6+ system
was used, the pooled odds ratio for cervical cancer
associated with the presence of any HPV type was
158.2. When the MY09/MY11 primers were used,
the pooled odds ratios were 63.4 and 19.1 in Spain
and Colombia, respectively. The overall estimates
of the odds ratio did not vary significantly according
to age group. Adjustment for age slightly increased
the odds ratios.
The adjusted odds ratios for the various HPV
types are shown in Table 4. Data on patients and
controls in Spain and Colombia have been exclud-
ed, because they were tested with a less sensitive
PCR assay. For HPV types 16, 18, 31, 33, 35, 45,
51, 52, 56, 58, 59, 68, and 73, the odds ratios were
results
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on July 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;6
 
www.nejm.org february 
 
6, 2003
 
epidemiologic classification of hpv types associated with cervical cancer
 
523
 
over 45 and the lower confidence limits were all
higher than 4.0. They were therefore classified as
high-risk types.
HPV types 39 and 82 were also classified as high-
risk types, because they were detected in some pa-
tients but in none of the 1928 controls. Because
types 26, 53, and 66 were detected in only one to
three patients, these types were classified as prob-
able high-risk types (Table 1).
HPV types 40, 42, 43, 44, 54, 61, 70, 72, and
CP6108 were not detected in patients and were
considered low-risk types. Types 6, 11, and 81 were
 
* P for trend among patients ≤0.05.
† P for trend among patients ≤0.001.
 
‡ HPV type X denotes specimens that were positive with the GP5+/6+ system but that did not hybridize with any of the 33 probes.
 
Table 2. Prevalence of Human Papillomavirus (HPV) Types in Patients with Squamous-Cell Cervical Cancer and Control Women Infected
with Single or Multiple Types, According to Age.
HPV Type Patients Controls
 
≤34 yr 35–49 yr ≥50 yr ≤34 yr 35–49 yr ≥50 yr
 
no. 
% of infected
patients no. 
% of infected
patients no. 
% of infected
patients no.
% of infected
controls no. 
% of infected
controls no. 
% of infected
controls
 
16* 175 64.1 417 60.0 433 56.2 12 28.6 29 24.8 29 29.0
18 33 12.1 113 16.3 114 14.8 0 0.0 14 12.0 12 12.0
45 14 5.1 54 7.8 34 4.4 4 9.5 6 5.1 8 8.0
31 11 4.0 33 4.7 29 3.8 5 11.9 5 4.3 7 7.0
52† 1 0.4 11 1.6 34 4.4 0 0.0 3 2.6 3 3.0
33 8 2.9 27 3.9 29 3.8 3 7.1 2 1.7 4 4.0
58* 3 1.1 15 2.2 26 3.4 2 4.8 3 2.6 6 6.0
35 6 2.2 7 1.0 21 2.7 2 4.8 4 3.4 4 4.0
59 1 0.4 10 1.4 12 1.6 0 0.0 0 0.0 2 2.0
51 1 0.4 10 1.4 9 1.2 1 2.4 4 3.4 1 1.0
56 0 0.0 6 0.9 10 1.3 2 4.8 2 1.7 3 3.0
39* 0 0.0 5 0.7 11 1.4 0 0.0 0 0.0 1 1.0
73 0 0.0 4 0.6 6 0.8 1 2.4 1 0.9 0 0.0
82 1 0.4 0 0.0 5 0.6 1 2.4 1 0.9 0 0.0
26 1 0.4 0 0.0 4 0.5 0 0.0 0 0.0 0 0.0
66 1 0.4 3 0.4 5 0.6 0 0.0 0 0.0 0 0.0
68 0 0.0 2 0.3 1 0.1 1 2.4 0 0.0 2 2.0
53 1 0.4 1 0.1 1 0.1 0 0.0 0 0.0 0 0.0
6 2 0.7 4 0.6 3 0.4 4 9.5 4 3.4 5 5.0
81 0 0.0 0 0.0 2 0.3 1 2.4 2 1.7 5 5.0
70 0 0.0 0 0.0 2 0.3 0 0.0 5 4.3 2 2.0
Others 2 0.7 7 1.0 5 0.6 7 16.7 13 11.1 13 13.0
X*‡ 30 11.0 35 5.0 46 6.0 7 16.7 32 27.4 15 15.0
Total no. of infected 
women
273 100.0 695 100.0 771 100.0 42 100.0 117 100.0 100 100.0
Total no. of infections 291 — 764 — 842 — 53 — 130 — 122 —
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each detected  in only 1 of the 1598 patients positive
for single HPV types, and were therefore also clas-
sified as low-risk types (Table 1). Although the odds
ratios for types 6 and 11 were 4.3 and 11.2, respec-
tively, the lower limits of their confidence intervals
were 0.5 and 1.0, respectively, further supporting
their classification in the low-risk group.
The odds ratio for infection with multiple HPV
types was not significantly different from that for
infection with a single type (odds ratio for cervical
cancer associated with multiple as compared with
single infection, 0.7; 95 percent confidence inter-
val, 0.4 to 1.0).
When our epidemiologic classification was com-
pared with the phylogenetic grouping (Table 5), a
discrepancy was observed only for two types: HPV
type 70, which was classified as a high-risk type phy-
logenetically but as a low-risk type by our epidemi-
ologic study; and HPV type 73, which was classified
as a low-risk type phylogenetically but a high-risk
type epidemiologically.
No significant interactions were detected be-
tween HPV type and other known risk factors, such
as high parity, long-term use of oral contraceptives,
smoking, and age at first sexual intercourse (data
not shown).
Our pooled analysis of 11 case–control studies pro-
vides robust estimates of the risk of squamous-cell
carcinoma of the cervix linked to 30 HPV types. Our
best estimate of the pooled odds ratio for squa-
mous-cell cervical carcinoma associated with HPV
DNA positivity is 158.2 (Table 3). The association
with the less common types is of a strength similar
to the association found with HPV types 16 and 18.
Retesting of all patients who were negative for
HPV DNA, but of only a small proportion of con-
trols who were negative for HPV DNA, as well as the
use of biopsy specimens from some of the patients,
could have led to overestimation of the true odds
ratios associated with HPV infection. However, we
believe that any potential bias is likely to be small
and would not substantially modify our results. In
our validation studies in Peru, 19 of the 29 patients
originally classified as negative for HPV DNA were
reclassified as positive after retesting with E7 pri-
mers, whereas none of the controls were reclassi-
fied as positive.
 
19
 
 Similarly, in another study carried
out in Thailand, the Philippines, and Spain, the prev-
alence of HPV DNA in exfoliated cells was very close
to that in cervical-biopsy specimens from women
without cervical cancer who were undergoing hys-
terectomy.
 
26
 
Our epidemiologic classification, based on
HPV-type–specific odds ratios and HPV prevalence
among patients and controls, identified 15 HPV
types as high-risk types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82). Three types (26,
53, and 66) should be considered probable high-
risk types, since they were detected in only one to
three patients and in none of the controls. Twelve
types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and
CP6108) were categorized as low-risk types, and
three types (34, 57, and 83) were detected in none
of the samples and were therefore considered to be
associated with undetermined risk. According to
the results of our study, five types that others have
classified as low-risk types
 
10,27
 
 or as types associ-
ated with undetermined risk (26, 53, 66, 73, and 82)
should now be added to the list of high-risk or prob-
able high-risk types. The commercially available Hy-
brid Capture II (Digene) high-risk HPV test includes
all of the types we have classified as high-risk types
discussion
 
* Testing was performed with the GP5+/6+ primers, except in Spain and Colombia, 
where the MY09/MY11 primers were used. For all countries except Spain and Co-
lombia, only invasive cancer was studied.
† The odds ratios have been adjusted for age. CI denotes confidence interval.
 
‡ The odds ratio has been adjusted for age and center.
 
Table 3. Risk of Squamous-Cell Cervical Cancer Associated with the Presence
of Human Papillomavirus (HPV) DNA.*
Country Patients Controls Odds Ratio (95% CI)†
 
no.
% HPV-
positive no.
% HPV-
positive
 
Brazil 169 97.0 196 17.3 177.0 (65.5–478.3)
Mali 65 96.9 12 33.3 109.2 (10.6–1119.0)
Morocco 175 97.1 176 21.6 113.7 (42.3–305.3)
Paraguay 106 98.1 91 19.8 208.1 (46.4–932.8)
Philippines 331 96.4 381 9.2 276.8 (139.7–548.3)
Thailand 339 96.5 261 15.7 163.5 (82.0–325.9)
Peru 171 95.3 175 17.7 115.9 (48.6–276.4)
Total‡ 1356 96.6 1292 15.6 158.2 (113.4–220.6)
Spain
Invasive
In situ
316
159
157
77.8
82.4
73.2
329
136
193
5.2
5.9
4.7
63.4 (36.4–110.6)
75.7 (32.9–174.2)
58.9 (27.4–126.7)
Colombia
Invasive
In situ
246
111
135
74.4
78.4
71.1
307
126
181
13.4
17.5
10.5
19.1 (12.3–29.6)
17.7 (9.1–34.3)
21.1 (11.5–38.8)
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* CI denotes confidence interval, HR high-risk types, and LR low-risk types. Women from Spain and Colombia have been excluded 
from this analysis.
† The odds ratios were adjusted for age and center.
‡ HPV type X denotes specimens that were positive with the GP5+/6+ system but that did not hybridize with any of the 33 probes.
§ This category includes HPV types 26, 66, 82, and HR.
 
¶ This category includes HPV types 54, 43, 40, 42, 44, 61, 70, 72, and CP6108.
 
Table 4. Risk of Squamous-Cell Cervical Cancer According to Human Papillomavirus (HPV) Type.*
HPV Type Patients Controls Odds Ratio (95% CI)†
 
no. % no. %
 
Negative for HPV 46 3.4 1091 84.4 1.0
16 685 50.5 42 3.3 434.5 (278.2–678.7)
18 177 13.1 17 1.3 248.1 (138.1–445.8)
45 74 5.5 9 0.7 197.6 (91.7–425.7)
31 36 2.7 8 0.6 123.6 (53.5–286.0)
52 37 2.7 4 0.3 200.0 (67.8–590.1)
33 14 1.0 1 0.1 373.5 (46.7–2985.8)
58 31 2.3 6 0.5 114.8 (45.1–292.6)
35 15 1.1 6 0.5 73.8 (26.4–206.5)
59 17 1.3 1 0.1 419.2 (54.2–3242.4)
51 13 1.0 4 0.3 66.5 (20.0–221.0)
56 9 0.7 5 0.4 45.1 (14.0–145.3)
39 8 0.6 0 0.0 —
73 5 0.4 1 0.1 106.4 (11.4–991.8)
68 2 0.2 1 0.1 53.7 (4.4–650.1)
6 1 0.1 6 0.5 4.3 (0.5–38.4)
11 1 0.1 2 0.2 11.2 (1.0–128.0)
81 0 0.0 6 0.5 —
X‡ 47 3.5 34 2.6 32.9 (19.1–56.6)
Other single HR§ 10 0.7 0 0.0 —
Other single LR¶ 0 0.1 19 1.5 —
16 and other LR 5 0.4 1 0.1 130.8 (14.7–1161.7)
16 and other HR 23 1.7 1 0.1 617.4 (80.8–4716.4)
16 and 18 36 2.7 3 0.2 327.2 (95.7–1119.1)
18 and other HR 21 1.5 3 0.2 187.0 (52.8–662.3)
Other double infections 29 2.1 15 1.2 52.3 (25.6–106.7)
Triple infections 10 0.7 4 0.3 65.4 (19.3–221.7)
Quadruple or quintuple infections 3 0.2 2 0.2 32.5 (5.1–206.8)
Total women 1356 100.0 1292 100.0
Multiple infections 127 9.4 29 2.2 114.9 (68.8–191.7)
Single infections 1183 87.2 172 13.3 172.6 (122.2–243.7)
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except types 26, 53, 66, 73, and 82.
 
10
 
 Our results
indicate that this assay would have missed 18 of
1598 infections in patients (1.1 percent) and 1 of
223 in controls (0.4 percent).
We confirmed the low-risk status of six types
widely regarded as such (types 6, 11, 40, 42, 43, and
44) and added to this list types 54, 61, 70, 72, 81,
and CP6108, which have been considered as types
associated with undetermined risk by others. Fur-
ther studies will be required to determine the epi-
demiologic classification of HPV types not assessed
in our study, such as types 62 and 67, which are clas-
sified phylogenetically as low-risk and high-risk
types, respectively.
This pooled analysis provided us with the op-
portunity to compare epidemiologic and phyloge-
netic classifications of HPV types. The concordance
of these two classifications is remarkable (Table 5);
discrepancies were found only for types 70 and 73.
Little is known about the transforming or onco-
genic properties of the 
 
E6
 
 and 
 
E7
 
 genes of HPV types
other than those of the prototype high-risk types (16
and 18) and low-risk types (6 and 11). Types 16 and
18, as well as types 31 and 33, but not types 6 and 11,
can induce immortalization of primary human ke-
ratinocytes and rat kidney cells.
 
28-30
 
The prevalence of multiple HPV infections var-
ies in relation to the method used to detect HPV
DNA.
 
10
 
 In our study, the use of the PCR assay with
the GP5+/6+ primer system may have led to an un-
derestimation of the prevalence of multiple infec-
tions. As in previous studies, infection by multiple
HPV types in our study was not associated with a
greater risk of cervical cancer than infection by a
single HPV type.
 
27,31
 
HPV type 16 was the only type whose incidence
decreased significantly with age. Assessment of
the distribution of HPV types in cervical cancer over
the past four to five decades is needed to determine
whether these age-related differences are due to a
cohort effect that could predict changes in the dis-
tribution of HPV types in the years to come, with
implications for HPV-vaccination efforts. 
Types 16, 18, 45, 31, 33, 52, 58, and 35 account-
ed for 95 percent of the squamous-cell carcinomas
positive for HPV DNA. These findings have impor-
tant implications for the prevention of cervical can-
cer. They imply that an effective vaccine against the
five most common HPV types could prevent about
90 percent of the cases of cervical cancer worldwide.
However, regional variation in the distribution of
certain HPV types should be taken into account in
the creation of vaccines tailored to different geo-
graphic regions.
Our results also have important implications
for patient care and screening strategies. The sim-
ilarity of the odds ratios for individual high-risk
HPV types and their combinations clearly indicates
that testing for groups of high-risk HPV types is
sufficient and that the composition of screening
“cocktails” for high-risk HPV types could be re-
vised in view of our results and those from other
populations.
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The International Agency for Research on Cancer Multicenter Cervical Cancer Study Group is composed of the following researchers: N.
Muñoz, S. Franceschi, M. Plummer, and J. Smith (International Agency for Research on Cancer, Lyons, France); F.X. Bosch, V. Moreno, S.
de Sanjosé, and X. Castellsagué (Institut Català d’Oncologia, Barcelona, Spain); R. Herrero (Foundation for Health Sciences, San José, Cos-
ta Rica); C.J.L.M. Meijer, J.M.M. Walboomers (deceased), A.J.C. van den Brule, and P.J.F. Snijders (Vrije Universiteit Medical Center, Amster-
dam); K.V. Shah (Johns Hopkins University, Baltimore); S. Chichareon (Prince of Songkla University, Hat-Yai, Thailand); C. Ngelangel (Uni-
versity of the Philippines, Manila); N. Chaouki and B. El Gueddari (Institut National d’Oncologie, Rabat, Morocco); J. Eluf Neto (São Paulo
 
* The epidemiologic classification of these types as probable 
high-risk types is based on zero controls and one to three 
 
positive cases.
 
Table 5. Phylogenetic and Epidemiologic Classification 
of HPV Types.
Phylogenetic
Classification Epidemiologic Classification
 
High risk Low risk
High risk 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 
68, 82, 26,* 53,* 66*
70
Low risk 73 6, 11, 40, 42, 43, 44, 
54, 61, 72, 81, 
CP6108
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cunce (Breast Cancer Prevention Center, Pamplona, Spain); L.C. González (Delegation of Social Welfare, Salamanca, Spain); M. Santamaria
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